trending Market Intelligence /marketintelligence/en/news-insights/trending/SODBI-inkoEEK_EsCcO8NA2 content esgSubNav
In This List

US FDA grants pediatric exclusivity to AstraZeneca's asthma inhaler

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


US FDA grants pediatric exclusivity to AstraZeneca's asthma inhaler

The U.S. FDA granted AstraZeneca PLC's Symbicort inhalation aerosol six months of pediatric exclusivity.

The decision was based on the evaluation of trials in children aged 6 to 12 years with asthma, in response to a written request by the company.

Symbicort is approved in the U.S. to treat asthma in patients 12 years and older. The inhaler is also approved for the maintenance treatment of chronic obstructive pulmonary disease in adults.